An mRNA-based vaccine strategy against Zika

Wong, Gary; Gao, George F.

doi:10.1038/cr.2017.53

Cited by 6 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IgEsig-prM-E-LNP, an mRNA vaccine, was synthesized by chemically containing modified nucleoside 1-methylpseudouridine, 5′ and 3′ untranslated regions with poly-A, human IgE (the signal sequence IgEsig), and nucleoside-modified ZIKV full-length prM-E genes, and was encapsulated in lipid nanoparticles (LNPs) [ 126 ]. This vaccine was applied to mice infected with ZIKV, and could effectively induce an immune response [ 127 ]. Another advantage of mRNA is that it can modify genes.…”

Section: Vaccines Of Flavivirusmentioning

confidence: 99%

Flavivirus: From Structure to Therapeutics Development

Zhao

Wang

Cao

et al. 2021

Life

View full text Add to dashboard Cite

Flaviviruses are still a hidden threat to global human safety, as we are reminded by recent reports of dengue virus infections in Singapore and African-lineage-like Zika virus infections in Brazil. Therapeutic drugs or vaccines for flavivirus infections are in urgent need but are not well developed. The Flaviviridae family comprises a large group of enveloped viruses with a single-strand RNA genome of positive polarity. The genome of flavivirus encodes ten proteins, and each of them plays a different and important role in viral infection. In this review, we briefly summarized the major information of flavivirus and further introduced some strategies for the design and development of vaccines and anti-flavivirus compound drugs based on the structure of the viral proteins. There is no doubt that in the past few years, studies of antiviral drugs have achieved solid progress based on better understanding of the flavivirus biology. However, currently, there are no fully effective antiviral drugs or vaccines for most flaviviruses. We hope that this review may provide useful information for future development of anti-flavivirus drugs and vaccines.

show abstract

Section: Vaccines Of Flavivirusmentioning

confidence: 99%

Flavivirus: From Structure to Therapeutics Development

Zhao

Wang

Cao

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…Vaccine technologies under development for the pandemic flu response could also be applied to TB. One such approach uses mRNA as a vaccine vector 11 . These mRNA vaccines yield high level in vivo Ag expression and are relatively simple to manufacture enabling them to be tested against multiple pathogens with relative ease.…”

Section: Tb Vaccine Technologiesmentioning

confidence: 99%

Progress and challenges in TB vaccine development

et al. 2018

View full text Add to dashboard Cite

The Bacille Calmette Guerin (BCG) vaccine can provide decades of protection against tuberculosis (TB) disease, and although imperfect, BCG is proof that vaccine mediated protection against TB is a possibility. A new TB vaccine is, therefore, an inevitability; the question is how long will it take us to get there? We have made substantial progress in the development of vaccine platforms, in the identification of antigens and of immune correlates of risk of TB disease. We have also standardized animal models to enable head-to-head comparison and selection of candidate TB vaccines for further development. To extend our understanding of the safety and immunogenicity of TB vaccines we have performed experimental medicine studies to explore route of administration and have begun to develop controlled human infection models. Driven by a desire to reduce the length and cost of human efficacy trials we have applied novel approaches to later stage clinical development, exploring alternative clinical endpoints to prevention of disease outcomes. Here, global leaders in TB vaccine development discuss the progress made and the challenges that remain. What emerges is that, despite scientific progress, few vaccine candidates have entered clinical trials in the last 5 years and few vaccines in clinical trials have progressed to efficacy trials. Crucially, we have undervalued the knowledge gained from our “failed” trials and fostered a culture of risk aversion that has limited new funding for clinical TB vaccine development. The unintended consequence of this abundance of caution is lack of diversity of new TB vaccine candidates and stagnation of the clinical pipeline. We have a variety of new vaccine platform technologies, mycobacterial antigens and animal and human models. However, we will not encourage progression of vaccine candidates into clinical trials unless we evaluate and embrace risk in pursuit of vaccine development.

show abstract

“…E protein is the key component in vaccine formulation of flaviviruses (21). Progress in vaccine development against ZIKV has been made in multiple platforms, including DNA plasmid-based (22,23), mRNA-based (24)(25)(26), and rhesus adenovirus-vectored (RhAd52) (27) vaccines incorporating the ZIKV prM/E or M/E genes, as well as inactivated (23,27) and live attenuated vaccines (28). E-specific humoral responses represent the key correlates of protection (23).…”

mentioning

confidence: 99%